Physician profile
Mandy Warthan
NPI 1982737102
$2,234.21
in general payments reported to CMS, 2019-2025
27 companies · $40.48 in 2025
The $40.48 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $566 · 2020: $106 · 2021: $594 · 2022: $557 · 2023: $320 · 2024: $51.91 · 2025: $40.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $412.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $598.53 | 2019-2022 | |
| Abbvie INC. | $231.54 | 2019-2023 | Rinvoq |
| Solta Medical, A Division of Bausch Health US, LLC | $191.88 | 2021-2022 | |
| Allergan, INC. | $139.54 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $138.24 | 2019-2022 | |
| Janssen Biotech, INC. | $115.32 | 2019-2023 | Tremfya |
| Sun Pharmaceutical Industries INC. | $113.96 | 2019-2022 | |
| Leo Pharma INC. | $113.52 | 2023 | Adbry |
| Biofrontera INC. | $85.48 | 2019-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Pfizer INC. | $70.72 | 2022-2024 | |
| Lilly USA, LLC | $68.96 | 2019-2023 | Olumiant, Taltz |
| Regeneron Healthcare Solutions, INC. | $55.61 | 2019-2025 | Dupixent |
| Promius Pharma LLC | $41.14 | 2019 | |
| Aclaris Therapeutics, INC. | $32.35 | 2019 | |
| Amgen INC. | $27.00 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Prugen, INC. Pharmaceuticals | $23.74 | 2019 | |
| Kerecis Limited | $23.63 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Organogenesis INC. | $22.64 | 2023 | Puraply |
| Taro Pharmaceuticals USA, INC. | $20.41 | 2019 | |
| Ucb, INC. | $19.47 | 2023 | Cimzia |
| Novartis Pharmaceuticals Corporation | $15.66 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.54 | 2022 | |
| Almirall LLC | $14.50 | 2024 | Klisyri |
| Medimetriks Pharmaceuticals, INC. | $14.00 | 2019 | |
| Strata Skin Sciences, INC. | $13.96 | 2025 | Xtrac |
| Dermavant Sciences, INC. | $13.75 | 2023 | Vtama |
| Galderma Laboratories, L.P. | $13.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandy Warthan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.